Biofidelity was improving
January 3, 2025 at 4:51 AM
Biofidelity was improving
A new study from Biofidelity is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage non-small cell lung cancer (NSCLC) patients from receiving molecular profiling and, as a result, highly effective targeted therapies.+
January 24, 2025 at 10:29 PM
A new study from Biofidelity is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage non-small cell lung cancer (NSCLC) patients from receiving molecular profiling and, as a result, highly effective targeted therapies.+
#genomicsolutions #MolecularDiagnostics #Biofidelity #oncology #genomics4all #CellCarta #AspyreLung #precisionmedicine #nonsmallcelllungcancer #NSCLC #NSCLCbiomarkers #genomicservices #clinicaltrialenrolment #SimplifiedGenomicProfiling #SGP #qPCRplatforms
pharmatimes.com/news/biofide...
pharmatimes.com/news/biofide...
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials - PharmaTimes
New partnership to advance precision medicine in lung cancer diagnosis
pharmatimes.com
January 20, 2025 at 3:20 PM
CellCarta and Biofidelity Forge Exclusive Partnership for Aspyre® Lung Testing#Cambridge#United_Kingdom#Biofidelity#CellCarta#Aspyre_Lung
CellCarta and Biofidelity Forge Exclusive Partnership for Aspyre® Lung Testing
CellCarta and Biofidelity have expanded their partnership to exclusively offer Aspyre® Lung for targeted lung cancer testing, streamlining clinical trials.
third-news.com
March 19, 2026 at 12:52 PM
CellCarta and Biofidelity Forge Exclusive Partnership for Aspyre® Lung Testing#Cambridge#United_Kingdom#Biofidelity#CellCarta#Aspyre_Lung
Biofidelity Unveils Revolutionary Enspyre® Technology at AGBT 2025#United_States#Florida#Biofidelity#Enspyre#Genomic_Technology
Biofidelity Unveils Revolutionary Enspyre® Technology at AGBT 2025
Biofidelity is set to debut its groundbreaking sequencing technology, Enspyre®, aimed at enhancing genomic analysis for cancer diagnostics at AGBT 2025.
third-news.com
February 20, 2025 at 1:30 PM
Biofidelity Unveils Revolutionary Enspyre® Technology at AGBT 2025#United_States#Florida#Biofidelity#Enspyre#Genomic_Technology
Biofidelity and CellCarta's Innovative Approach to Clinical Trials Launching Aspyre® Lung#Cambridge#United_Kingdom#Biofidelity#CellCarta#Aspyre_Lung
Biofidelity and CellCarta's Innovative Approach to Clinical Trials Launching Aspyre® Lung
Biofidelity partners with CellCarta to implement Aspyre® Lung in global clinical trials, advancing cancer diagnosis with innovative genomic solutions.
third-news.com
January 9, 2025 at 1:34 PM
Biofidelity and CellCarta's Innovative Approach to Clinical Trials Launching Aspyre® Lung#Cambridge#United_Kingdom#Biofidelity#CellCarta#Aspyre_Lung
Composite Biofidelity: Addressing Metric Degeneracy in Biomechanical Model Validation and Machine Learning Loss Design https://www.biorxiv.org/content/10.64898/2026.04.05.716563v1
April 8, 2026 at 7:46 PM
Composite Biofidelity: Addressing Metric Degeneracy in Biomechanical Model Validation and Machine Learning Loss Design https://www.biorxiv.org/content/10.64898/2026.04.05.716563v1
Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem.
#BLOODPAC #Biofidelity
#BLOODPAC #Biofidelity
December 3, 2025 at 3:04 PM
Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem.
#BLOODPAC #Biofidelity
#BLOODPAC #Biofidelity
Composite Biofidelity: Addressing Metric Degeneracy in Biomechanical Model Validation and Machine Learning Loss Design https://www.biorxiv.org/content/10.64898/2026.04.05.716563v1
April 8, 2026 at 7:46 PM
Composite Biofidelity: Addressing Metric Degeneracy in Biomechanical Model Validation and Machine Learning Loss Design https://www.biorxiv.org/content/10.64898/2026.04.05.716563v1
Composite Biofidelity: Addressing Metric Degeneracy in Biomechanical Model Validation and Machine Learning Loss Design [new]
Multi-metric for obj spec biofid. Single metrics misld. Consensus improves biomech model val & ML loss des.
Multi-metric for obj spec biofid. Single metrics misld. Consensus improves biomech model val & ML loss des.
April 8, 2026 at 7:54 PM
Composite Biofidelity: Addressing Metric Degeneracy in Biomechanical Model Validation and Machine Learning Loss Design [new]
Multi-metric for obj spec biofid. Single metrics misld. Consensus improves biomech model val & ML loss des.
Multi-metric for obj spec biofid. Single metrics misld. Consensus improves biomech model val & ML loss des.
